Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 142 No. 1718 (2012)

Assisted reproductive medicine in Switzerland

  • Christian De Geyter
DOI
https://doi.org/10.4414/smw.2012.13569
Cite this as:
Swiss Med Wkly. 2012;142:w13569
Published
22.04.2012

Abstract

Since the first introduction of hormonal contraception, family planning and procreation have become increasingly medicalised. The rapid spread of assisted reproductive technology (ART) is part of this natural development of modern society. However, in Switzerland it has caused severe controversy and its use has been framed by a restrictive legislation since 2001. Despite this, the yearly number of reported treatments with in-vitro fertilisation (IVF), with intracytoplasmic sperm injection (ICSI) and with transfer of frozen/thawed oocytes in the pronucleate stage has risen to more than 10,000 in 2011. As over time the protocols for ovarian stimulation have reached higher levels of efficacy and as the composition of the culture media used for embryo development in the laboratory has become more elaborate, the implantation rate of the transferred embryos has steadily improved leading to higher pregnancy rates, but also resulting in a higher risk of multiple delivery. Deliveries of multiples, including those with twins, often occur prematurely causing significant maternal and neonatal morbidity and mortality. Improved assessment of the developmental potential of embryos together with better freezing protocols have lead to the selection and transfer of one single embryo per treatment cycle in an increasing number of countries but not in Switzerland. This strategy has been shown to be very effective in preventing multiple deliveries without compromising the overall pregnancy rates. In addition, well accepted treatment modalities in assisted reproduction, such as embryo cryopreservation, oocyte donation and preimplantation genetic diagnosis have not been implemented in Switzerland due to the current restrictive legislation. The still present ban on cryopreservation of embryos in Switzerland now leads to a higher incidence of complications and neonatal death than necessary in the presence of an adapted legal environment. There is an urgent need for a public debate about the future role of modern reproductive medicine in Swiss society. This discussion should focus not only on the risks of ART but also on its opportunities.

References

  1. Germond M, Senn A. A law affecting assisted procreation is on the way in Switzerland. J Assist Reprod Genet. 1999;16:341–3.
  2. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet. 1978;2(8085):366.
  3. Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992;340(8810):17–8.
  4. Bunge RG, Keettel WC, Sherman JK. Clinical use of frozen semen: report of four cases. Fertil Steril. 1954;5(6):520–9.
  5. Rabau E, David A, Serr DM, Mashiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. Am J Obstet Gynecol. 1967;98(1):92–8.
  6. Odell WD, Ross GT, Rayford PL. Radioimmunoassay for luteinizing hormone in human plasma or serum: physiological studies. J Clin Invest. 1967;46(2):248–55.
  7. Whitten WK, Biggers JD. Complete development in vitro of the pre-implantation stages of the mouse in a simple chemically defined medium. J Reprod Fertil. 1968;17(2):399–401.
  8. Lopata A, Patullo MJ, Chang A, James B. A method for collecting motile spermatozoa from human semen. Fertil Steril. 1976;27(6):677–84.
  9. Bundesamt für Statistik, Medienmitteilung 22.02.2011
  10. De Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V, et al.; European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE. Hum Reprod. 2010;25(8):1851–62.
  11. Connolly MP, Hoorens S, Chambers GM; ESHRE Reproduction and Society Task Force. The costs and consequences of assisted reproductive technology: an economic perspective. Hum Reprod Update. 2010;16(6):603–13.
  12. Jones HW Jr, Jones GS, Andrews MC, Acosta A, Bundren C, Garcia J, et al. The program for in vitro fertilization at Norfolk. Fertil Steril. 1982;38(1):14–21.
  13. Kemeter P, Feichtinger W. Trans-vaginal oocyte retrieval using a trans-vaginal sector scan probe combined with an automated puncture device. Hum Reprod. 1986;1(1):21–4.
  14. Sallam HN, Sadek SS. Ultrasound-guided embryo transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 2003;80(4):1042–6.
  15. Germond M, Dessole S, Senn A, Loumaye E, Howles C, Beltrami V. Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH. Lancet. 1992;9;339(8802):1170.
  16. Devroey P, van Steirteghem A, Mannaerts B, Bennink HC. Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH. Lancet. 1992;339(8802):1170.
  17. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;(5):CD001750.
  18. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, Aboulfoutouh I, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;(1):CD008046.
  19. Blake DA, Farquhar CM, Johnson N, Proctor M. Cleavage stage versus blastocyst stage embryo transfer in assisted conception. Cochrane Database Syst Rev. 2007;(4):CD002118.
  20. Van den Bergh M, Hohl MK, De Geyter Ch, Stalberg AM, Limoni C. Ten years of Swiss National IVF Register FIVNAT-CH. Are we making progress? Reprod Biomed Online. 2005;11(5):632–40.
  21. Karlström PO, Bergh C. Reducing the number of embryos transferred in Sweden-impact on delivery and multiple birth rates. Hum Reprod. 2007;22(8):2202–7.
  22. Van Landuyt L, Verheyen G, Tournaye H, Camus M, Devroey P, Van Steirteghem A. New Belgian embryo transfer policy leads to sharp decrease in multiple pregnancy rate. Reprod Biomed Online. 2006;13(6):765–71.
  23. De Geyter M, Steimann S, Holzgreve W, De Geyter C. First delivery of healthy offspring after freezing and thawing of oocytes in Switzerland. Swiss Med Wkly. 2007;137(31-32):443–7.
  24. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96(2):277–85.
  25. Boulet SL, Schieve LA, Nannini A, Ferre C, Devine O, Cohen B, et al. Perinatal outcomes of twin births conceived using assisted reproduction technology: a population-based study. Hum Reprod. 2008;23(8):1941–8.
  26. Connolly MP, Hoorens S, Chambers GM; ESHRE Reproduction and Society Task Force. The costs and consequences of assisted reproductive technology: an economic perspective. Hum Reprod Update. 2010;16(6):603–13.
  27. De Geyter C, Boehler B, Reiter-Theil S. Differences and similarities in the attitudes of paediatricians, gynaecologists and experienced parents to criteria delineating potential risks for the welfare of children to be conceived with assisted reproduction. Swiss Med Wkly. 2010;140:w13064.